This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
== Mathematical models == There are several mathematical models that describe collective cell motion. Typically, a Newtonian equation of motion for a system of cells is solved. Several forces act on each individual cell, examples are friction (between environment and other cells), chemotaxis and self-propulsion. The latter implies that cells are active matter far from thermal equilibrium that are able to generate force due to myosin-actin contractile motion. An overview over physical description of collective cell migration explains that the following types of models can be used:
Inosine 5′-monophosphate dehydrogenase (IMPDH) is a purine biosynthetic enzyme that catalyzes the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), the first committed and rate-limiting step towards the de novo biosynthesis of guanine nucleotides from IMP. IMPDH is a regulator of the intracellular guanine nucleotide pool, and is therefore important for DNA and RNA synthesis, signal transduction, energy transfer, glycoprotein synthesis, as well as other processes that are involved in cellular proliferation.
=== Awards === In 2003, the Laténium received the European Museum of the Year Award awarded by the Council of Europe the for its contribution for a better understanding of the european cultural heritage. The Laténium was the first swiss museum to receive the award. In 2018, it received the Medal for archaeological mediation of the International Union for Prehistoric and Protohistoric Sciences. The Laténium's commitment to the popularisation of archaeology and for the social valorisation of the protection of the cultural heritage got the museum the award.
== In vitro == Theanine is structurally similar to the excitatory neurotransmitter glutamate and binds to glutamate receptors in vitro, though with much lower affinity in comparison. Specifically, it binds to ionotropic glutamate receptors in the micromolar range, including the AMPA and kainate receptors and, to a lesser extent, the NMDA receptor. It acts as an antagonist of the former two sites, and a partial co-agonist of the NMDA receptors. In vitro, theanine also binds to group I mGluRs. In addition, it inhibits glutamine transporters and glutamate transporters, and thus blocks the reuptake of glutamine and glutamate. Theanine may elicit umami taste, a consequence potentially associated with binding to and activation of the T1R1 + T1R3 heterodimer or umami (savory) taste receptor.
Nevertheless, without clear biosynthetic pathways (not yet found in animals, but shown for bacteria), it remains uncertain whether it is simply via bacteria that each animal accumulates TTX; the question remains as to whether the quantities can be sufficiently explained by ingestion, ingestion plus colonization, or some other mechanism.
Sources: en.wikipedia.org
Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for vitamins and minerals, PRIs for the European Union (same concept as RDAs), followed by what three government organizations deem to be the safe upper intake. RDAs are set higher than EARs to cover people with higher-than-average needs. Adequate Intakes (AIs) are set when there is insufficient information to establish EARs and RDAs. Countries establish tolerable upper intake levels, also referred to as upper limits (ULs), based on amounts that cause adverse effects. Governments are slow to revise information of this nature. For the U.S. values, except calcium and vitamin D, all data date from 1997 to 2004.
Ruling by decree, the RCC maintained the monarchy's ban on political parties, banned trade unions, and in 1972 outlawed workers' strikes and suspended newspapers. In September 1971, Gaddafi resigned, claiming dissatisfaction with the pace of reform, but returned to his position within a month. In July 1972, amid widespread speculation that Gaddafi had been ousted or jailed by his political opponents, a new 18-man cabinet was formed with only two, Jalloud and Abdel Moneim al-Houni, being military men; the rest were civilian technocrats per Gaddafi's insistence. In February 1973, Gaddafi resigned again, once more returning the next month.
R5P consists of a five-carbon sugar, ribose, and a phosphate group at the five-position carbon. It can exist in open chain form or in furanose form. The furanose form is most commonly referred to as ribose 5-phosphoric acid.
The alignment (polarization) of the magnetic nuclear spins in an applied, constant magnetic field B0. The perturbation of this alignment of the nuclear spins by a weak oscillating magnetic field, usually referred to as a radio frequency (RF) pulse. The oscillation frequency required for significant perturbation is dependent upon the static magnetic field (B0) and the nuclei of observation. The detection of the NMR signal during or after the RF pulse, due to the voltage induced in a detection coil by precession of the nuclear spins around B0. After an RF pulse, precession usually occurs with the nuclei's Larmor frequency and, in itself, does not involve transitions between spin states or energy levels. The two magnetic fields are usually chosen to be perpendicular to each other as this maximizes the NMR signal strength. The frequencies of the time-signal response by the total magnetization (M) of the nuclear spins are analyzed in NMR spectroscopy and magnetic resonance imaging. Both use applied magnetic fields (B0) of great strength, usually produced by large currents in superconducting coils, in order to achieve dispersion of response frequencies and of very high homogeneity and stability in order to deliver spectral resolution, the details of which are described by chemical shifts, the Zeeman effect, and Knight shifts (in metals). The information provided by NMR can also be increased using hyperpolarization, and/or using two-dimensional, three-dimensional and higher-dimensional techniques.
=== Binding === DCBQ is an electrophilic compound, so it can bind in the human body to multiple nucleophilic compounds. DCBQ can, for instance, react with GSH, substituting the Cl groups for the GS group. DCBQ is thus being dechlorinated and can undergo Michael addition with GSH, resulting in more glutathionylated products. The second Cl group can also be removed from the compound when reacting with another GSH molecule. DCBQ can also undergo redox reactions when reacting with an electron, forming radicals. These radicals can also react with GSH, forming more conjugation products. DCBQ can also react with amino acids. When DCBQ was brought in contact with amino acids, the DCBQ was quickly removed, suggesting that the DCBQ reacted with the amino acids. DCBQ binds to the DNA via H-bonds, a non-covalent interaction. Because of its hydrophobicity, DCBQ might be intercalated between nucleotides in a double-stranded DNA molecule [source]. This intercalation might lead to increased access to the nucleotides, possibly leading to even more oxidative damage in the DNA. Amino acids can also covalently bind to DCBQ. The amino acids undergo nucleophilic substitution with both DCBQ and DCBQ-OH, the product of DCBQ hydrolysis. Proteins can be bound by DCBQ covalently via cysteine or lysine residues. Catechins, which are naturally present in for instance green tea, can competitively bind to DCBQ, reducing the amount of proteins bound to DCBQ [16]. The proteins are covalently modified when bound to DCBQ, which might change the stability and alter the function of the protein.
Sources: en.wikipedia.org
=== Trump administration === After Harris was defeated by former president Donald Trump in the general election on November 5, 2024, Moore pledged to work with the Trump administration, but said he would push back when necessary. He also pledged to defend Marylanders' constitutional rights, and restore faith in public institutions and democracy during Trump's second presidency. By February 2025, Moore maintained that he would still be open to working with anyone to advance Maryland's interests, but expressed pessimism toward being able to partner with the Trump administration, adding that he planned to use the power of his office to counter Trump—including executive orders and backing federal litigation filed by Maryland Attorney General Anthony Brown against several of Trump's actions—and criticizing the president for dismantling federal departments, furloughing thousands of federal workers, and starting tariff wars. Moore opposed the One Big Beautiful Bill Act, calling it "one of the worst bills for working families that our country has ever proposed" and predicting that it would result in one of the largest upward transfers of wealth from the poor to the rich in American history through cuts to federal assistance programs and tax cuts for wealthy individuals and big corporations.
Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc., an affiliate of Beiersdorf AG. The brand was introduced in the United States in 1925. In accordance with the Food and Drug Administration's OTC Skin Protectant Monograph, Aquaphor contains 41 percent petrolatum (petroleum jelly) as its active ingredient. It is used to temporarily protect minor cuts, scrapes, and burns, as well as chapped or cracked skin. The product line includes ointments for compounding, general skin therapy, lip repair, and baby care. Aquaphor is used and recommended by health care professionals for minor post-operative wounds or defects.
=== SCTECH - Supply Chain Technology Conference and Expo === Since 2016 ISCEA has sponsored and managed a supply chain technology conference and expo named SCTECH. Besides being a Supply Chain, Operations, Engineering and Technology professionals gathering, SCTECH provides Professional Development Units (PDUs) to ISCEA's certified professional so that they can renew their certification credentials. The event has an itinerant nature. Its first edition was held in Chicago and following editions were held in Mexico and Paris. Since 2023, SCTECH has offered a Virtual Program with global outreach, along with an In-Person Executive Program for Supply Chain Leaders. The Executive Programs for both the 2023 and 2024 editions took place at SAP’s World Headquarters in Walldorf, Germany.
=== Food supplement === The valuable cannabinoids, proteins, vitamins, minerals, polyphenols, and poly-unsaturated fatty acids are useful to prevent deficiencies and aid muscle growth. Athletes for instance use protein powder made from hemp. Hemp juice offers a natural alternative to the industrially produced hemp protein. Even the dietary fibers in the press remnants can be used for food supplements if fermented. Finely ground hemp press remnants can substitute some portion of flour in bread recipes with yeast.
Hypoglycemia (American English), also spelled hypoglycaemia or hypoglycæmia (British English), sometimes called low blood sugar, is a fall in blood sugar to levels below normal, typically below 70 mg/dL (3.9 mmol/L). Whipple's triad is used to properly identify hypoglycemic episodes. It is defined as blood glucose below 70 mg/dL (3.9 mmol/L), symptoms associated with hypoglycemia, and resolution of symptoms when blood sugar returns to normal. Hypoglycemia may result in headache, tiredness, clumsiness, trouble talking, confusion, fast heart rate, sweating, shakiness, nervousness, hunger, loss of consciousness, seizures, or death. Symptoms typically come on quickly. Symptoms can persist after blood-glucose levels are restored to normal. The most common cause of hypoglycemia is medications used to treat diabetes such as insulin, sulfonylureas, and biguanides. Risk is greater in people with diabetes who have eaten less than usual, recently exercised, or consumed alcohol. Other causes of hypoglycemia include severe illness, sepsis, kidney failure, liver disease, hormone deficiency, tumors such as insulinomas or non-B cell tumors, inborn errors of metabolism, and several medications. Low blood sugar may occur in otherwise healthy newborns who have not eaten for a few hours. Hypoglycemia is treated by eating a sugary food or drink, for example glucose tablets or gel, apple juice, soft drinks, or lollipops. The person must be conscious and able to swallow. The goal is to consume 10–20 grams of a carbohydrate to raise blood glucose levels to a minimum of 70 mg/dL (3.9 mmol/L).
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.